EVCARCO, Inc. (OTC.BB:EVCA) would like to update you on some recent events and developments affecting the Company.
1. On August 25, 2010, for personal reasons, Mr. Dale Long resigned from the Board of Directors and his position of President/CEO. As part of the separation, the Company has retired 13,625,900 shares of common stock, or 17.62% of outstanding shares; and reduced current liabilities by approximately $70,000. Mr. Long will make every effort to continue the relationship and assist EVCARCO as an unaffiliated consultant.
2. EVCA board approves the creation of its Ambassador Sustainability Living Program aimed at creating significant links with Hollywood’s most eco-friendliest celebrities as well as major global influencers. The concept has been approved by the board and EVCARCO will proudly be announcing the first of the Hollywood celebrities to participate in the program soon. This initiative is poised to be a gain significant attention for EVCARCO’s green vehicles.
3. Along with the current program for putting environmentally friendly vehicles in governmental fleets, we are focusing more attention on building strategic alliances in order to develop technologies for military applications, to participate in contracts for Defense Vehicle Engineering Design, Development, Integration and Testing.
4. As part of continued expansion efforts, EVCARCO has initiated development of the following programs with the Governments of Columbia and Peru: Alternative Energy and fleet replacement, Federal Government support and Electric Vehicle Sales, Mass Transit Vehicle programs for large cities.
5. EVCARCO has approved a program to initiate market research in order to stimulate public market awareness regarding the corporation and its growth potential. The program will create stronger ties between the Company and the public markets by educating and providing key information to the investors.
6. EVCARCO is working to create additional networks of alternative energy vehicles. The enhancement of EVCARCO’s product line is anticipated to create stronger revenues in the fourth quarter of the current year.
PROTEONOMIX, INC. (OTC.BB:PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, reports that Mr. Michael Cohen, Chairman and CEO, is scheduling a multi-city European road trip to create additional awareness of the Proteonomix, Inc. investment opportunity to institutional investors.
Scheduled for early October, Mr. Cohen will discuss with sophisticated investors the recent contract to establish a joint venture with a group of investors that will establish a new stem cell treatment and research facility in the United Arab Emirates (U.A.E.). In addition, Mr. Cohen will discuss the opportunity to set up additional joint ventures in other countries using the U.A.E. arrangement as a model.
Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. is a wholly owned subsidiary of Proteonomix that has recently opened its retail web site, Proteoderm.com, and begun accepting pre-orders for its anti-aging line of skin care products. StromaCel, Inc.’s goal is the development therapeutic modalities for the treatment of Cardiovascular Disease (CVD). StromaCel, Inc. is pursuing the licensing of other technologies for therapeutic use. National Stem Cell, Inc. is Proteonomix’s operating subsidiary. The Sperm Bank of New York, Inc. is a fully operational tissue bank. Proteonomix Regenerative Translational Medicine Institute, Inc. (“PRTMI”) intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies.
Celldex Therapeutics, Inc. (Nasdaq: CLDX) will regain full worldwide rights to develop and commercialize rindopepimut (CDX-110), effective November 1, 2010. Celldex and Pfizer Vaccines LLC entered into a global development and commercialization agreement in April 2008 for rindopepimut, an experimental therapeutic cancer vaccine that targets the tumor-specific molecule epidermal growth factor receptor variant III (EGFRvIII) in patients with Glioblastoma Multiforme (GBM). Pfizer has informed Celldex that the rindopepimut program is no longer a strategic priority of Pfizer and has terminated the agreement. As previously disclosed, across three clinical studies, rindopepimut has met or exceeded all pre-determined safety and efficacy objectives.
“There is a significant need for new therapies for GBM and we are fully committed to developing rindopepimut for the patients who suffer from this fatal disease,” said Anthony Marucci, President and Chief Executive Officer of Celldex Therapeutics. “Importantly, the program has advanced significantly, including the completion of a multi-center Phase 2 study, the development of a diagnostic companion product, the manufacture of drug supply for clinical studies, and the execution of discussions with regulatory agencies on the design of a global controlled study. We believe the program is very well-positioned to advance into pivotal clinical studies and that the GBM market remains extremely attractive.”
“Rindopepimut is widely perceived by clinicians as one of the most promising non-toxic drug candidates for a patient population that has very limited treatment options,” commented Tom Davis, M.D., Chief Medical Officer of Celldex Therapeutics. “Moving forward, we remain committed to the brain cancer patient and physician community and to the continued development of rindopepimut.”
Tesla Motors (Nasdaq:TSLA), manufacturer of the only highway-capable electric performance vehicle, the Tesla Roadster, reports that the Roadster has been approved for the Japanese government�s Clean Energy Cash Rebate Program.
The Clean Energy Cash Rebate Program is aimed at promoting the accelerated adoption of electric vehicles or plug-in hybrids. The Tesla Roadster is only the second standard-sized car, following the plug-in Prius by Toyota, to qualify. It is also the only qualified import vehicle. Each Tesla Roadster buyer is eligible to receive a cash rebate of up to 3.24 million yen, approximately $38,000 US at current exchange rates.
The handmade, carbon fiber Roadster is the only car that delivers supercar performance with zero tailpipe emissions. It accelerates from 0-100km in less than four seconds � faster than most sports cars � yet consumes no petroleum. The Roadster plugs into any conventional socket and can travel over 394 kilometers on a single charge. It is the only sports car in the world that can be charged with solar, hydro or wind energy.
Palo Alto, CA-based Tesla designs and manufactures EVs and EV powertrain components. It has delivered more than 1200 Roadsters to customers in North America, Europe and Asia. Tesla�s goal is to produce increasingly affordable electric cars for mainstream buyers � relentlessly driving down the cost of EVs. It is currently the only automaker in the U.S. that builds and sells highway-capable EVs in serial production.
Tesla entered Japan in May of this year, and has begun deliveries of its Signature Series Roadsters to pioneer customers. The base Roadster, which starts at 12.8 million yen, including tax but before the Cash Rebate, is available for custom orders immediately.
No comments:
Post a Comment